Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to 102.85%.

  • Lineage Cell Therapeutics' EBIT Margin fell 12400.0% to 102.85% in Q3 2025 from the same period last year, while for Sep 2025 it was 325.27%, marking a year-over-year decrease of 645700.0%. This contributed to the annual value of 226.11% for FY2024, which is 503900.0% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported EBIT Margin of 102.85% as of Q3 2025, which was down 12400.0% from 715.37% recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' EBIT Margin ranged from a high of 56.48% in Q4 2021 and a low of 1803.07% during Q1 2021
  • Over the past 5 years, Lineage Cell Therapeutics' median EBIT Margin value was 301.45% (recorded in 2021), while the average stood at 419.31%.
  • In the last 5 years, Lineage Cell Therapeutics' EBIT Margin surged by 16809400bps in 2022 and then crashed by -3629700bps in 2023.
  • Lineage Cell Therapeutics' EBIT Margin (Quarter) stood at 56.48% in 2021, then crashed by -514bps to 346.68% in 2022, then rose by 12bps to 304.69% in 2023, then surged by 42bps to 178.17% in 2024, then soared by 42bps to 102.85% in 2025.
  • Its EBIT Margin stands at 102.85% for Q3 2025, versus 715.37% for Q2 2025 and 433.09% for Q1 2025.